Additionally, in two different case series studies of PLWH on cART and treated for a variety of malignancies, an excellent tolerability of anti-PD-1 and/or anti-PD-L1 therapy was observed, and all patients showed stable CD4 T-cell counts and no reactivation of HIV load during ICI therapy (93, 94). Here, PDCD1 is linked to cancer.